Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ICLR's Cash to Debt is ranked higher than
84% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. ICLR: No Debt )
ICLR' s 10-Year Cash to Debt Range
Min: 0.96   Max: No Debt
Current: No Debt

Equity to Asset 0.63
ICLR's Equity to Asset is ranked higher than
65% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. ICLR: 0.63 )
ICLR' s 10-Year Equity to Asset Range
Min: 0.53   Max: 0.77
Current: 0.63

0.53
0.77
Interest Coverage 94.07
ICLR's Interest Coverage is ranked higher than
65% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.50 vs. ICLR: 94.07 )
ICLR' s 10-Year Interest Coverage Range
Min: 17.93   Max: 9999.99
Current: 94.07

17.93
9999.99
F-Score: 7
Z-Score: 5.17
M-Score: -2.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 6.79
ICLR's Operating margin (%) is ranked higher than
78% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. ICLR: 6.79 )
ICLR' s 10-Year Operating margin (%) Range
Min: 2.27   Max: 12.11
Current: 6.79

2.27
12.11
Net-margin (%) 5.76
ICLR's Net-margin (%) is ranked higher than
79% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. ICLR: 5.76 )
ICLR' s 10-Year Net-margin (%) Range
Min: 1.76   Max: 13.44
Current: 5.76

1.76
13.44
ROE (%) 11.29
ICLR's ROE (%) is ranked higher than
85% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. ICLR: 11.29 )
ICLR' s 10-Year ROE (%) Range
Min: 3.36   Max: 17.12
Current: 11.29

3.36
17.12
ROA (%) 7.13
ICLR's ROA (%) is ranked higher than
83% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. ICLR: 7.13 )
ICLR' s 10-Year ROA (%) Range
Min: 2.23   Max: 10.38
Current: 7.13

2.23
10.38
ROC (Joel Greenblatt) (%) 63.02
ICLR's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. ICLR: 63.02 )
ICLR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 11.88   Max: 63.02
Current: 63.02

11.88
63.02
Revenue Growth (%) 11.20
ICLR's Revenue Growth (%) is ranked higher than
82% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.90 vs. ICLR: 11.20 )
ICLR' s 10-Year Revenue Growth (%) Range
Min: -14.6   Max: 54.5
Current: 11.2

-14.6
54.5
EBITDA Growth (%) 8.70
ICLR's EBITDA Growth (%) is ranked higher than
76% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. ICLR: 8.70 )
ICLR' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 36.6
Current: 8.7

0
36.6
EPS Growth (%) 4.60
ICLR's EPS Growth (%) is ranked higher than
73% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. ICLR: 4.60 )
ICLR' s 10-Year EPS Growth (%) Range
Min: -34.2   Max: 54.4
Current: 4.6

-34.2
54.4
» ICLR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ICLR Guru Trades in Q1 2013

Ron Baron 822,800 sh (New)
Jim Simons 155,460 sh (New)
RS Investment Management 444,800 sh (+18.51%)
Jean-Marie Eveillard 12,000 sh (unchged)
Caxton Associates Sold Out
Meridian Funds 308,000 sh (-33.19%)
Steven Cohen 21,210 sh (-47.06%)
Chuck Royce 386,400 sh (-59.79%)
» More
Q2 2013

ICLR Guru Trades in Q2 2013

Paul Tudor Jones 150,000 sh (New)
Steven Cohen 60,275 sh (+184.18%)
Jim Simons 283,160 sh (+82.14%)
Ron Baron 1,022,800 sh (+24.31%)
Jean-Marie Eveillard 12,000 sh (unchged)
Meridian Funds 308,000 sh (unchged)
Stanley Druckenmiller Sold Out
RS Investment Management 430,460 sh (-3.22%)
Chuck Royce 267,348 sh (-30.81%)
» More
Q3 2013

ICLR Guru Trades in Q3 2013

Jim Simons 495,160 sh (+74.87%)
Ron Baron 1,280,000 sh (+25.15%)
RS Investment Management 470,360 sh (+9.27%)
Jean-Marie Eveillard 12,000 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 210,200 sh (-21.38%)
Steven Cohen 9,031 sh (-85.02%)
» More
Q4 2013

ICLR Guru Trades in Q4 2013

Paul Tudor Jones 200,000 sh (New)
Steven Cohen 219,406 sh (+2329.48%)
Jim Simons 830,860 sh (+67.8%)
Ron Baron 1,430,000 sh (+11.72%)
RS Investment Management 500,960 sh (+6.51%)
Chuck Royce 210,200 sh (unchged)
Jean-Marie Eveillard 12,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ICLR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2013-09-30 Add 25.15%0.05%$36.24 - $40.67 $ 43.914%1280000
Ron Baron 2013-06-30 Add 24.31%0.04%$29.2 - $36.22 $ 43.933%1022800
Meridian Funds 2013-03-31 Reduce -33.19%0.17%$27.25 - $32.91 $ 43.947%308000
Ron Baron 2013-03-31 New Buy0.15%$27.25 - $32.91 $ 43.947%822800
Meridian Funds 2012-12-31 Reduce -28.22%0.16%$23.46 - $28.54 $ 43.966%461000
Meridian Funds 2012-06-30 Add 24.87%0.1%$20.51 - $23.23 $ 43.9101%642200
Meridian Funds 2012-03-31 Add 25.16%0.06%$17.06 - $22.01 $ 43.9131%514300
Jean-Marie Eveillard 2011-09-30 Add 36.36%$16.5 - $25.21 $ 43.9113%15000
Meridian Funds 2011-06-30 New Buy0.24%$21.18 - $25.92 $ 43.983%351000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Icon PLC

Baron Funds Comments on ICON PLC - Jun 10, 2013

Other purchases in the quarter include ICON plc (ICLR), which is a CRO (Contract Research Organization) providing outsourced drug research to the pharmaceutical industry. We observed from our investment in Covance that the industry is turning, so we purchased a stake in ICON to increase the Fund's exposure to the trend.

From Baron Funds’ first quarter 2013 commentary.
Check out Ron Baron latest stock trades

Top Ranked Articles about Icon PLC

Baron Funds Comments on ICON PLC
Other purchases in the quarter include ICON plc (ICLR), which is a CRO (Contract Research Organization) providing outsourced drug research to the pharmaceutical industry. We observed from our investment in Covance that the industry is turning, so we purchased a stake in ICON to increase the Fund's exposure to the trend. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 26.50
ICLR's P/E(ttm) is ranked higher than
59% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.50 vs. ICLR: 26.50 )
ICLR' s 10-Year P/E(ttm) Range
Min: 4.19   Max: 78.79
Current: 26.5

4.19
78.79
P/B 3.10
ICLR's P/B is ranked higher than
65% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. ICLR: 3.10 )
ICLR' s 10-Year P/B Range
Min: 0.46   Max: 5.55
Current: 3.1

0.46
5.55
P/S 1.50
ICLR's P/S is ranked higher than
78% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.63 vs. ICLR: 1.50 )
ICLR' s 10-Year P/S Range
Min: 0.52   Max: 2.14
Current: 1.5

0.52
2.14
PFCF 14.50
ICLR's PFCF is ranked higher than
82% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.36 vs. ICLR: 14.50 )
ICLR' s 10-Year PFCF Range
Min: 5.14   Max: 600.13
Current: 14.5

5.14
600.13
EV-to-EBIT 20.40
ICLR's EV-to-EBIT is ranked higher than
58% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.08 vs. ICLR: 20.40 )
ICLR' s 10-Year EV-to-EBIT Range
Min: 1.4   Max: 50.5
Current: 20.4

1.4
50.5
PEG 16.60
ICLR's PEG is ranked lower than
67% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. ICLR: 16.60 )
ICLR' s 10-Year PEG Range
Min: 0.08   Max: 16.3
Current: 16.6

0.08
16.3
Shiller P/E 33.10
ICLR's Shiller P/E is ranked higher than
62% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. ICLR: 33.10 )
ICLR' s 10-Year Shiller P/E Range
Min: 6.42   Max: 36.3
Current: 33.1

6.42
36.3

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 41.40
ICLR's Price/Net Current Asset Value is ranked lower than
84% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.40 vs. ICLR: 41.40 )
ICLR' s 10-Year Price/Net Current Asset Value Range
Min: 3.69   Max: 57.18
Current: 41.4

3.69
57.18
Price/Tangible Book 5.10
ICLR's Price/Tangible Book is ranked lower than
51% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. ICLR: 5.10 )
ICLR' s 10-Year Price/Tangible Book Range
Min: 0.64   Max: 4.74
Current: 5.1

0.64
4.74
Price/DCF (Projected) 1.60
ICLR's Price/DCF (Projected) is ranked higher than
85% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. ICLR: 1.60 )
ICLR' s 10-Year Price/DCF (Projected) Range
Min: 0.52   Max: 6.85
Current: 1.6

0.52
6.85
Price/Median PS Value 1.50
ICLR's Price/Median PS Value is ranked higher than
65% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ICLR: 1.50 )
ICLR' s 10-Year Price/Median PS Value Range
Min: 0.49   Max: 1.39
Current: 1.5

0.49
1.39
Price/Graham Number 2.40
ICLR's Price/Graham Number is ranked lower than
53% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. ICLR: 2.40 )
ICLR' s 10-Year Price/Graham Number Range
Min: 0.42   Max: 2.36
Current: 2.4

0.42
2.36
Earnings Yield (Greenblatt) 4.90
ICLR's Earnings Yield (Greenblatt) is ranked higher than
62% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. ICLR: 4.90 )
ICLR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2   Max: 71.7
Current: 4.9

2
71.7
Forward Rate of Return (Yacktman) -1.94
ICLR's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. ICLR: -1.94 )
ICLR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -16.2   Max: 62
Current: -1.94

-16.2
62

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Icon PLC is a contract research organization that provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It develops, manages, and analyses programs that support all stages of clinical development process - from compound selection to Phase I-IV clinical studies. The Company provides its customers clinical research services which include: clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide